Posts

Two UTA professors selected as Fulbright scholars

Two University of Texas at Arlington faculty members have received Fulbright U.S...

Collaborative seed grants nurture high-impact social an...

The National Science Foundation, the National Institutes of Health, and the Nati...

NSF CAREER award invests in the future of stable computing

Every night, uncounted numbers of devices across the globe update their operatin...

Poignant photo project reveals all we lost in lockdown

Laptops and schoolwork on kitchen tables, a deserted playground, face masks on a...

The picture of health: Virginia Tech researchers enhanc...

Imagine you just swallowed a pill containing a miniature camera that will help y...

Marine fossils unearth story about Panama’s deep past

Between 6.4 and 5.8 million years ago, most of the land bridge that connects Nor...

Fungi blaze a trail to fireproof cladding

Mycelium, an incredible network of fungal strands that can thrive on organic was...

Investigating interactions at molecular junctions for n...

The structure of a molecular junction with noncovalent interaction plays a key r...

Multisensory information detection by using multi-chann...

Overview Credit: COPYRIGHT (C) TOYOHASHI UNIVERSITY OF TECHNOLOGY. ALL RIGHTS RE...

Unexpected coupling with leaky mode unveils new path fo...

Defying conventional wisdom, researchers have uncovered a novel coupling mechani...

Europe conducting review of potential suicide risks ass...

The European Medicines Agency (EMA) has launched a thorough review of Novo Nordi...

Tessa Therapeutics dissolves company

Tessa Therapeutics, a biotech company based in Singapore, has halted its operati...

Israeli company bags $4.2m contract to develop cell the...

Pluri signed a 3-year contract to develop cell therapy to treat acute radiation ...

Roche’s Columvi receives marketing approval in Europe

The European Commission has granted conditional marketing authorisation for Colu...

Iovance looks to advance its non-small cell lung cancer...

Iovance Biotherapeutics completes a preliminary analysis after the US' FDA found...

Fulcrum and CAMP4 to develop rare blood disorder therapies

Fulcrum Therapeutics has signed a licence agreement with CAMP4 Therapeutics to d...